Latest stories on ENSC
Ensysce Biosciences, Inc. (ENSC) files 8-K
SEC 8-K50 · neutralgeneral
Ensysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Development
InvestorsHub67 · bullishgeneral
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study | ENSC Stock News
StockTitan63 · neutralproduct/pr
Ensysce Biosciences GAAP EPS of -$0.52 beats by $0.21
Seeking Alpha56 · neutralearnings
Ensysce Biosciences Reports First Quarter 2026 Financial Results
Morningstar50 · neutralgeneral